Matches in Wikidata for { <http://www.wikidata.org/entity/Q83795026> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q83795026 description "clinical trial" @default.
- Q83795026 description "ensayu clínicu" @default.
- Q83795026 description "klinisch onderzoek" @default.
- Q83795026 description "клінічне випробування" @default.
- Q83795026 name "Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma" @default.
- Q83795026 name "Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma" @default.
- Q83795026 type Item @default.
- Q83795026 label "Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma" @default.
- Q83795026 label "Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma" @default.
- Q83795026 prefLabel "Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma" @default.
- Q83795026 prefLabel "Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma" @default.
- Q83795026 P1050 Q83795026-26F2D406-FB88-463F-B10C-8CBD7F42E77D @default.
- Q83795026 P1132 Q83795026-70AFB2B1-B53D-4BAB-9531-BC58BDA8471F @default.
- Q83795026 P1476 Q83795026-3BC57537-378E-4F7A-8D1A-575896A6B40F @default.
- Q83795026 P2899 Q83795026-1FC40437-8A45-4692-8B92-D23F78EA9B62 @default.
- Q83795026 P3098 Q83795026-EC9FFF87-A124-43BD-9382-35F5B7C3AB86 @default.
- Q83795026 P31 Q83795026-15558E9C-AFC4-4021-ADF4-CC468C3C0B86 @default.
- Q83795026 P580 Q83795026-0397C0FC-D740-4F0F-995C-374BA017F84F @default.
- Q83795026 P582 Q83795026-A96CB04F-5DB0-4A81-B933-F86EA31F75E4 @default.
- Q83795026 P6099 Q83795026-B1353221-C8E3-417E-A144-65073593B4AD @default.
- Q83795026 P8363 Q83795026-443C0B34-A0A9-4918-ADF6-16F089C88EC5 @default.
- Q83795026 P859 Q83795026-515A7A40-8C5C-452A-A4C2-E72F9787713B @default.
- Q83795026 P1050 Q356033 @default.
- Q83795026 P1132 "+68" @default.
- Q83795026 P1476 "Neoadjuvant Durvalumab (MEDI4736) Plus Docetaxel, Oxaliplatin, S-1 (DOS) Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient (pMMR) Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma" @default.
- Q83795026 P2899 "+19" @default.
- Q83795026 P3098 "NCT04221555" @default.
- Q83795026 P31 Q30612 @default.
- Q83795026 P580 "2020-02-13T00:00:00Z" @default.
- Q83795026 P582 "2022-02-28T00:00:00Z" @default.
- Q83795026 P6099 Q42824440 @default.
- Q83795026 P8363 Q78089383 @default.
- Q83795026 P859 Q4803501 @default.